Last reviewed · How we verify

Norethisterone,Ethinylestradiol — Competitive Intelligence Brief

Norethisterone,Ethinylestradiol (Norethisterone,Ethinylestradiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: progestogen-estrogen combination. Area: Women's Health.

phase 3 progestogen-estrogen combination progesterone receptor, estrogen receptor Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Norethisterone,Ethinylestradiol (Norethisterone,Ethinylestradiol) — Nobelpharma. Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Norethisterone,Ethinylestradiol TARGET Norethisterone,Ethinylestradiol Nobelpharma phase 3 progestogen-estrogen combination progesterone receptor, estrogen receptor
YAZ® YAZ® Teva Pharmaceuticals USA marketed Oral contraceptive (combined estrogen-progestin) Progesterone receptor, estrogen receptor, mineralocorticoid receptor
norelgestromin + ethinyl estradiol norelgestromin + ethinyl estradiol Johnson & Johnson Pharmaceutical Research & Development, L.L.C. marketed Combined oral contraceptive (progestin + estrogen) Progesterone receptor, estrogen receptor
Intermittent OC (EE/DROS) Intermittent OC (EE/DROS) University of North Carolina, Chapel Hill marketed Oral contraceptive Progesterone receptor, estrogen receptor
Ortho Tri-Cyclen LO Ortho Tri-Cyclen LO Bristol-Myers Squibb marketed Oral contraceptive (combined hormonal contraceptive) Progesterone receptor, estrogen receptor
Nomegestrol Acetate / Estradiol Nomegestrol Acetate / Estradiol University of Palermo marketed Combined oral contraceptive Progesterone receptor, Estrogen receptor
Drospirenone / Estetrol Drospirenone / Estetrol University of Palermo marketed Combined oral contraceptive Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (progestogen-estrogen combination class)

  1. Nobelpharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norethisterone,Ethinylestradiol — Competitive Intelligence Brief. https://druglandscape.com/ci/norethisterone-ethinylestradiol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: